SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended May 31, 2003 File Number 0-288
Robbins & Myers, Inc
Ohio (State or other jurisdiction of incorporation or organization) |
31-0424220 (I.R.S. Employer Identification No.) |
1400 Kettering Tower, Dayton, Ohio (Address of Principal executive offices) |
45423 (Zip Code) |
Registrants telephone number including area code (937) 222-2610
None
Former name, former address and former fiscal year if changed since last report
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. YES X NO
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). YES X NO
Common shares, without par value, outstanding as of May 31, 2003: 14,378,600
1
ROBBINS & MYERS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEET
(In thousands)
May 31, | August 31, | ||||||||||
2003 | 2002 | ||||||||||
ASSETS |
(Unaudited) | ||||||||||
Current Assets
|
|||||||||||
Cash and cash equivalents |
$ | 9,196 | $ | 10,534 | |||||||
Accounts receivable |
113,089 | 113,711 | |||||||||
Inventories: |
|||||||||||
Finished products |
28,116 | 29,000 | |||||||||
Work in process |
35,792 | 22,487 | |||||||||
Raw materials |
40,760 | 40,959 | |||||||||
104,668 | 92,446 | ||||||||||
Other current assets |
10,933 | 12,318 | |||||||||
Deferred taxes |
13,607 | 14,071 | |||||||||
Total Current Assets |
251,493 | 243,080 | |||||||||
Goodwill |
302,021 | 271,948 | |||||||||
Other Intangible Assets |
17,535 | 17,604 | |||||||||
Other Assets |
6,991 | 6,201 | |||||||||
Property, Plant and Equipment |
286,168 | 261,926 | |||||||||
Less accumulated depreciation |
(138,975 | ) | (118,067 | ) | |||||||
147,193 | 143,859 | ||||||||||
$ | 725,233 | $ | 682,692 | ||||||||
LIABILITIES
AND SHAREHOLDERS EQUITY
|
|||||||||||
Current Liabilities
|
|||||||||||
Accounts payable |
$ | 48,464 | $ | 41,964 | |||||||
Accrued expenses |
85,810 | 83,871 | |||||||||
Current portion of long-term debt |
7,346 | 4,526 | |||||||||
Total Current Liabilities |
141,620 | 130,631 | |||||||||
Long-Term DebtLess Current Portion |
192,658 | 203,920 | |||||||||
Deferred Taxes |
8,827 | 8,708 | |||||||||
Other Long-Term Liabilities |
79,275 | 70,863 | |||||||||
Minority Interest |
9,116 | 8,347 | |||||||||
Shareholders Equity
|
|||||||||||
Common stock |
104,306 | 103,923 | |||||||||
Retained earnings |
183,702 | 176,627 | |||||||||
Accumulated other comprehensive loss |
5,729 | (20,057 | ) | ||||||||
293,737 | 260,493 | ||||||||||
$ | 725,233 | $ | 682,692 | ||||||||
See Notes to Consolidated Condensed Financial Statements
2
ROBBINS & MYERS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED INCOME STATEMENT
(In thousands, except per share data)
(Unaudited)
Three Months Ended | Nine Months Ended | ||||||||||||||||
May 31, | May 31, | ||||||||||||||||
2003 | 2002 | 2003 | 2002 | ||||||||||||||
Net sales |
$ | 144,921 | $ | 124,812 | $ | 403,904 | $ | 394,201 | |||||||||
Cost of sales |
95,782 | 83,419 | 267,970 | 262,342 | |||||||||||||
Gross profit |
49,139 | 41,393 | 135,934 | 131,859 | |||||||||||||
SG&A expenses |
37,146 | 31,640 | 106,938 | 97,073 | |||||||||||||
Amortization expense |
554 | 388 | 1,664 | 1,569 | |||||||||||||
Other |
0 | 0 | 0 | 0 | |||||||||||||
Income before interest and income taxes |
11,439 | 9,365 | 27,332 | 33,217 | |||||||||||||
Interest expense |
4,000 | 4,909 | 11,710 | 13,528 | |||||||||||||
Income before income taxes and minority
interest |
7,439 | 4,456 | 15,622 | 19,689 | |||||||||||||
Income tax expense |
2,488 | 1,490 | 5,230 | 6,590 | |||||||||||||
Minority interest |
540 | 270 | 948 | 792 | |||||||||||||
Net income |
$ | 4,411 | $ | 2,696 | $ | 9,444 | $ | 12,307 | |||||||||
Net income per share: |
|||||||||||||||||
Basic |
$ | 0.31 | $ | 0.23 | $ | 0.66 | $ | 1.04 | |||||||||
Diluted |
$ | 0.30 | $ | 0.23 | $ | 0.66 | $ | 0.99 | |||||||||
Dividends per share: |
|||||||||||||||||
Declared |
$ | 0.055 | $ | 0.055 | $ | 0.165 | $ | 0.165 | |||||||||
Paid |
$ | 0.055 | $ | 0.055 | $ | 0.165 | $ | 0.165 | |||||||||
See Notes to Consolidated Condensed Financial Statements
3
ROBBINS & MYERS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENT OF CASH FLOWS
(In thousands)
(Unaudited)
Nine Months Ended | ||||||||||||
May 31, | ||||||||||||
2003 | 2002 | |||||||||||
Operating Activities: |
||||||||||||
Net income |
$ | 9,444 | $ | 12,307 | ||||||||
Adjustments to reconcile net income to net cash and
cash equivalents provided by operating activities: |
||||||||||||
Depreciation |
15,588 | 15,286 | ||||||||||
Amortization |
1,664 | 1,569 | ||||||||||
Deferred taxes |
345 | (423 | ) | |||||||||
Performance stock awards |
0 | (126 | ) | |||||||||
Changes in operating assets and liabilities: |
||||||||||||
Accounts receivable |
12,365 | 3,204 | ||||||||||
Inventories |
(809 | ) | 15,071 | |||||||||
Accounts payable |
1,638 | (5,189 | ) | |||||||||
Accrued expenses |
(6,210 | ) | (7,722 | ) | ||||||||
Other |
(69 | ) | (3,238 | ) | ||||||||
Net Cash and Cash Equivalents Provided by Operating Activities |
33,956 | 30,739 | ||||||||||
Investing Activities: |
||||||||||||
Capital expenditures, net of nominal disposals |
(4,397 | ) | (12,648 | ) | ||||||||
Purchase of Tarby |
(12,478 | ) | 0 | |||||||||
Proceeds from sale of equipment |
0 | 4,905 | ||||||||||
Amended credit agreement fees |
0 | (1,871 | ) | |||||||||
Romaco earnout payment and acquisition costs |
0 | (19,794 | ) | |||||||||
Net Cash and Cash Equivalents Used by Investing Activities |
(16,875 | ) | (29,408 | ) | ||||||||
Financing Activities: |
||||||||||||
Proceeds from debt borrowings |
49,731 | 31,083 | ||||||||||
Payments of long-term debt |
(66,164 | ) | (43,274 | ) | ||||||||
Proceeds from sale of common stock |
383 | 3,755 | ||||||||||
Dividends paid |
(2,369 | ) | (1,951 | ) | ||||||||
Net Cash and Cash Equivalents Used by Financing Activities |
(18,419 | ) | (10,387 | ) | ||||||||
Decrease in Cash and Cash Equivalents |
(1,338 | ) | (9,056 | ) | ||||||||
Cash and Cash Equivalents at Beginning of Period |
10,534 | 16,122 | ||||||||||
Cash and Cash Equivalents at End of Period |
$ | 9,196 | $ | 7,066 | ||||||||
See Notes to Consolidated Condensed Financial Statements
4
ROBBINS & MYERS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
May 31, 2003
(Unaudited)
NOTE 1Preparation of Financial Statements
While we believe that the disclosures are adequately presented, it is suggested that these consolidated condensed financial statements be read in conjunction with the financial statements and notes included in our most recent Annual Report on Form 10-K for the fiscal year ended August 31, 2002. A summary of our significant accounting policies is presented therein on page 34. There have been no material changes in the accounting policies followed by us during fiscal year 2003.
NOTE 2New Accounting Standards
In December 2002, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards No. 148 (SFAS 148), Accounting for Stock-Based Compensation Transition and Disclosure. This Statement amends FASB Statement No. 123, Accounting for Stock-Based Compensation, to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, this Statement amends the disclosures in both annual and interim financial statements regarding the method of accounting for stock-based employee compensation and the effect of the method used on reported results. We continue to apply Accounting Principles Board Opinion No. 25 for the method used to account for stock-based employee compensation arrangements, where applicable, but have adopted the new disclosure requirements of SFAS 148 (see Note 9).
NOTE 3Acquisition
5
NOTE 4Goodwill and Other Intangible Assets
Pharmaceutical | Energy | Industrial | ||||||||||||||
Segment | Segment | Segment | Total | |||||||||||||
(In thousands) | ||||||||||||||||
Balance as of September 1, 2002 |
$ | 161,138 | $ | 68,098 | $ | 42,712 | $ | 271,948 | ||||||||
Goodwill acquired during the period |
0 | 0 | 8,384 | 8,384 | ||||||||||||
Translation adjustments and other |
19,823 | 1,588 | 278 | 21,689 | ||||||||||||
Balance as of May 31, 2003 |
$ | 180,961 | $ | 69,686 | $ | 51,374 | $ | 302,021 | ||||||||
Information regarding our other intangible assets is as follows:
As of May 31, 2003 | As of August 31, 2002 | ||||||||||||||||||||||||
Carrying | Accumulated | Carrying | Accumulated | ||||||||||||||||||||||
Amount | Amortization | Net | Amount | Amortization | Net | ||||||||||||||||||||
(In thousands) | |||||||||||||||||||||||||
Patents and
Trademarks |
8,117 | $ | 1,626 | $ | 6,491 | $ | 7,260 | $ | 1,103 | $ | 6,157 | ||||||||||||||
Non-compete
Agreements |
10,752 | 8,199 | 2,553 | 10,752 | 7,823 | 2,929 | |||||||||||||||||||
Financing
Costs |
7,366 | 4,068 | 3,298 | 6,668 | 3,363 | 3,305 | |||||||||||||||||||
Pension
Intangible |
4,564 | 0 | 4,564 | 4,564 | 0 | 4,564 | |||||||||||||||||||
Other |
2,078 | 1,449 | 629 | 2,038 | 1,389 | 649 | |||||||||||||||||||
Total |
$ | 32,877 | $ | 15,342 | $ | 17,535 | $ | 31,282 | $ | 13,678 | $ | 17,604 | |||||||||||||
6
NOTE 5Net Income per Share
Three Months Ended | Nine Months Ended | ||||||||||||||||||
May 31, | May 31, | ||||||||||||||||||
2003 | 2002 | 2003 | 2002 | ||||||||||||||||
(In thousands, except per share amounts) | |||||||||||||||||||
Numerator: |
|||||||||||||||||||
Basic: |
|||||||||||||||||||
Net income |
$ | 4,411 | $ | 2,696 | $ | 9,444 | $ | 12,307 | |||||||||||
Effect of dilutive securities: |
|||||||||||||||||||
Convertible debt interest |
575 | 582 | 1,757 | 1,746 | |||||||||||||||
Income attributable to diluted shares |
$ | 4,986 | $ | 3,278 | $ | 11,201 | $ | 14,053 | |||||||||||
Denominator: |
|||||||||||||||||||
Basic: |
|||||||||||||||||||
Weighted average shares |
14,373 | 11,894 | 14,358 | 11,833 | |||||||||||||||
Effect of dilutive securities: |
|||||||||||||||||||
Convertible debt |
2,135 | 2,191 | 2,194 | 2,191 | |||||||||||||||
Dilutive options and restricted shares |
26 | 118 | 29 | 138 | |||||||||||||||
Diluted shares |
16,534 | 14,203 | 16,581 | 14,162 | |||||||||||||||
Basic net income per share |
$ | 0.31 | $ | 0.23 | $ | 0.66 | $ | 1.04 | |||||||||||
Diluted net income per share-reported (a) |
$ | 0.30 | $ | 0.23 | $ | 0.66 | $ | 0.99 | |||||||||||
Diluted net income per share-computed (a) |
$ | 0.30 | $ | 0.23 | $ | 0.68 | $ | 0.99 | |||||||||||
(a) | For the nine month period ended May 31, 2003, the computed diluted net income per share is $0.68. However diluted net income per share may not exceed basic net income per share. Therefore the reported diluted net income per share for the nine month period ended May 31, 2003 is $0.66. |
NOTE 6Product Warranties
Changes in our product warranty liability during the period are as follows:
Nine Months Ended | ||||||||
May 31, | ||||||||
2003 | 2002 | |||||||
(In thousands) | ||||||||
Balance at beginning of the period |
$ | 9,405 | $ | 10,176 | ||||
Warranties issued during the period |
2,108 | 1,950 | ||||||
Settlements made during the period |
(2,443 | ) | (2,340 | ) | ||||
Changes in liability for pre-existing warranties during
the period, including
expirations |
(52 | ) | (261 | ) | ||||
Balance at end of the period |
$ | 9,018 | $ | 9,525 | ||||
7
NOTE 7Long-Term Debt
May 31, 2003 | |||||
(In thousands) | |||||
Senior debt: |
|||||
Revolving credit loan |
$ | 15,545 | |||
Senior notes |
100,000 | ||||
Other |
20,163 | ||||
10.00% subordinated notes |
24,296 | ||||
8.00% Convertible subordinated notes |
40,000 | ||||
Total debt |
200,004 | ||||
Less current portion |
7,346 | ||||
$ | 192,658 | ||||
Our Bank Credit Agreement (Agreement) provides that we may borrow on a revolving credit basis up to a maximum of $126,123,000. All outstanding amounts under the Agreement are due and payable on January 9, 2005. Interest is variable based upon formulas tied to LIBOR or prime, at our option, and is payable at least quarterly. At May 31, 2003 the weighted average interest rate for all amounts outstanding was 3.18%. Indebtedness under the Agreement is unsecured, except for guarantees by our U.S. subsidiaries, the pledge of the stock of our U.S. subsidiaries and the pledge of the stock of certain non-U.S. subsidiaries.
We have $100,000,000 of Senior Notes (Senior Notes) issued in two series. Series A in the principal amount of $70,000,000 has an interest rate of 6.76% and is due May 1, 2008, and Series B in the principal amount of $30,000,000 has an interest rate of 6.84% and is due May 1, 2010. Interest is payable semi-annually on May 1 and November 1.
The above agreements have certain restrictive covenants including limitations on cash dividends, treasury stock purchases and capital expenditures, and minimum requirements for interest coverage and leverage ratios. The amount of cash dividends and treasury stock purchases, other than in relation to stock option exercises, we may incur in each fiscal year is restricted to the greater of $3,500,000 or 50% of our consolidated net income for the immediately preceding fiscal year, plus a portion of any unused amounts from the preceding fiscal year. Under this Agreement and other lines of credit, we could incur additional indebtedness of approximately $15,000,000 based on our covenant position.
Our other debt primarily consists of unsecured non-U.S. bank lines of credit with interest rates ranging from 4.00% to 8.00%.
We have $24,296,000 of 10.00% Subordinated Notes (Subordinated Notes) with the former owner of Romaco. The Subordinated Notes are due in 2006 and 2007 and interest is payable quarterly.
We have $40,000,000 of 8.00% Convertible Subordinated Notes Due 2008 (8.00% Convertible Subordinated Notes). The 8.00% Convertible Subordinated Notes are due on January 31, 2008, bear interest at 8.00%, payable semi-annually on March 1 and September 1 and are convertible into common stock at a rate of $22.50 per share. Holders may convert at any time until maturity. The 8.00% Convertible Subordinated Notes are redeemable at our option at any time on or after March 1, 2004, at a redemption price (a) prior to or on March 1, 2005, equal to 102% of the principal amount, and (b) after March 1, 2005, equal to 100% of the principal amount.
The 8.00% Convertible Subordinated Notes and the Subordinated Notes are subordinated to all of our other indebtedness.
NOTE 8Income Taxes
8
NOTE 9Stock-Based Compensation
Three Months Ended | Nine Months Ended | ||||||||||||||||
May 31, | May 31, | ||||||||||||||||
2003 | 2002 | 2003 | 2002 | ||||||||||||||
(In thousands) | |||||||||||||||||
Net income, as reported |
$ | 4,411 | $ | 2,696 | $ | 9,444 | $ | 12,307 | |||||||||
Deduct: Total Stock-based employee
compensation expense determined under
fair value based method for all awards,
net
of related tax effects |
276 | 289 | 827 | 866 | |||||||||||||
Pro forma net income |
$ | 4,135 | $ | 2,407 | $ | 8,617 | $ | 11,441 | |||||||||
Earnings per share: |
|||||||||||||||||
Basicas reported |
$ | .31 | $ | .23 | $ | .66 | $ | 1.04 | |||||||||
Basicpro forma |
$ | .29 | $ | .20 | $ | .60 | $ | 0.97 | |||||||||
Dilutedas reported |
$ | .30 | $ | .23 | $ | .66 | $ | 0.99 | |||||||||
Dilutedpro forma |
$ | .28 | $ | .20 | $ | .60 | $ | 0.93 | |||||||||
NOTE 10Comprehensive Income
Three Months Ended | Nine Months Ended | ||||||||||||||||
May 31, | May 31, | ||||||||||||||||
2003 | 2002 | 2003 | 2002 | ||||||||||||||
(In thousands) | |||||||||||||||||
Net income |
$ | 4,411 | $ | 2,696 | $ | 9,444 | $ | 12,307 | |||||||||
Other comprehensive income: |
|||||||||||||||||
Foreign currency translation |
12,284 | 4,671 | 25,786 | 463 | |||||||||||||
Comprehensive income |
$ | 16,695 | $ | 7,367 | $ | 35,230 | $ | 12,770 | |||||||||
9
NOTE 11Business Segments
Three Months Ended | Nine Months Ended | ||||||||||||||||
May 31, | May 31, | ||||||||||||||||
2003 | 2002 | 2003 | 2002 | ||||||||||||||
(In thousands) | |||||||||||||||||
Unaffiliated customer sales: |
|||||||||||||||||
Pharmaceutical |
$ | 88,028 | $ | 73,071 | $ | 243,336 | $ | 235,854 | |||||||||
Industrial |
33,419 | 29,801 | 91,726 | 89,971 | |||||||||||||
Energy |
23,474 | 21,940 | 68,842 | 68,376 | |||||||||||||
Total |
$ | 144,921 | $ | 124,812 | $ | 403,904 | $ | 394,201 | |||||||||
EBIT: |
|||||||||||||||||
Pharmaceutical |
$ | 6,149 | $ | 5,365 | $ | 14,262 | $ | 22,718 | |||||||||
Industrial |
3,100 | 2,014 | 7,270 | 4,747 | |||||||||||||
Energy |
4,914 | 4,483 | 14,436 | 13,573 | |||||||||||||
Corporate and eliminations |
(2,724 | ) | (2,497 | ) | (8,636 | ) | (7,821 | ) | |||||||||
Total |
$ | 11,439 | $ | 9,365 | $ | 27,332 | $ | 33,217 | |||||||||
10
Part IManagements Discussion and Analysis of Financial Condition and Results of Operations
Results of Operations
The following tables present the components of our consolidated income statement and segment information for the three and nine month periods of fiscal 2003 and 2002.
Three Months Ended | Nine Months Ended | |||||||||||||||
May 31, | May 31, | |||||||||||||||
2003 | 2002 | 2003 | 2002 | |||||||||||||
Net Sales |
100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | ||||||||
Cost of sales |
66.1 | 66.8 | 66.3 | 66.6 | ||||||||||||
Gross profit |
33.9 | 33.2 | 33.7 | 33.4 | ||||||||||||
SG&A expenses |
25.6 | 25.4 | 26.5 | 24.6 | ||||||||||||
Amortization |
0.4 | 0.3 | 0.4 | 0.4 | ||||||||||||
Other |
0.0 | 0.0 | 0.0 | 0.0 | ||||||||||||
EBIT |
7.9 | % | 7.5 | % | 6.8 | % | 8.4 | % | ||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||||
May 31, | May 31, | |||||||||||||||||
2003 | 2002 | 2003 | 2002 | |||||||||||||||
(In thousands) | ||||||||||||||||||
Segment
|
||||||||||||||||||
Pharmaceutical:
|
||||||||||||||||||
Sales |
$ | 88,028 | $ | 73,071 | $ | 243,336 | $ | 235,854 | ||||||||||
EBIT |
6,149 | 5,365 | 14,262 | 22,718 | ||||||||||||||
EBIT % |
7.0 | % | 7.3 | % | 5.9 | % | 9.6 | % | ||||||||||
Industrial: |
||||||||||||||||||
Sales |
$ | 33,419 | $ | 29,801 | $ | 91,726 | $ | 89,971 | ||||||||||
EBIT |
3,100 | 2,014 | 7,270 | 4,747 | ||||||||||||||
EBIT % |
9.3 | % | 6.8 | % | 7.9 | % | 5.3 | % | ||||||||||
Energy: |
||||||||||||||||||
Sales |
$ | 23,474 | $ | 21,940 | $ | 68,842 | $ | 68,376 | ||||||||||
EBIT |
4,914 | 4,483 | 14,436 | 13,573 | ||||||||||||||
EBIT % |
20.9 | % | 20.4 | % | 21.0 | % | 19.9 | % |
Three months ended May 31, 2003
Net sales for the third quarter of fiscal 2003 were $144.9 million compared with $124.8 million in the third quarter of fiscal 2002.
The Pharmaceutical segment had sales of $88.0 million in the third quarter of fiscal 2003 compared with $73.1 million in the third quarter of fiscal 2002. The change in exchange rates, primarily the strengthening of the Euro, increased the third quarter of fiscal 2003 sales by $13.5 million compared with the third quarter of fiscal 2002. Excluding the impact of exchange rates, the third quarter of fiscal 2003 sales increased by $1.4 million, or 1.9%. Orders for this segment decreased from $91.0 million in the third quarter of fiscal 2002 to $81.0 million in the third quarter of fiscal 2003. The decrease in orders is due to economic weakness in many European countries. Backlog in this segment increased to $114.0 million at the end of the third quarter of fiscal 2003 from $100.8 million at August 31, 2002.
The Industrial segment had sales of $33.4 million in the third quarter of fiscal 2003 compared with $29.8 million in the third quarter of fiscal 2002. The increase in sales is primarily in our Industrial Pumps product platform from the acquisition of Tarby and municipal waste water treatment projects. Incoming orders in this segment were $33.4 million in the third quarter of fiscal 2003 compared with $27.8 million in the third quarter of fiscal 2002. The increased orders of $5.6 million, or 20.1%, were due to the acquisition
11
of Tarby, a large order in our Corrosion Resistant product platform and increased order activity in Asia. Backlog in this segment increased to $24.4 million at the end of the third quarter of fiscal 2003 from $21.6 million at August 31, 2002.
The Energy segment had sales of $23.5 million in the third quarter of fiscal 2003 compared with $21.9 million in the third quarter of fiscal 2002, an increase of $1.6 million or 7.3%. The overall level of crude oil and natural gas exploration and production activities has increased over the past few months. Incoming orders in this segment increased to $23.4 million in the third quarter of fiscal 2003, compared with $21.2 million in the third quarter of fiscal 2002. Backlog decreased marginally to $3.1 million at the end of the third quarter of fiscal 2003 from $3.3 million at August 31, 2002.
EBIT for the third quarter of fiscal 2003 was $11.4 million compared with $9.4 million in the third quarter of fiscal 2002.
The Pharmaceutical segment had EBIT of $6.1 million in the third quarter of fiscal 2003 compared with $5.4 million in the third quarter of fiscal 2002. The improvement in EBIT is due to the aforementioned increase in sales after considering the impact of exchange rates.
The Industrial segment had EBIT of $3.1 million in the third quarter of fiscal 2003 compared with $2.0 million in the third quarter of fiscal 2002, an increase of $1.1 million. The increase is due to higher sales volumes.
The Energy segment had EBIT of $4.9 million in the third quarter of fiscal 2003 compared with $4.5 million in the third quarter of fiscal 2002, an increase of $0.4 million or 8.9%. The Energy segment EBIT has increased again due to the sales volume increase mentioned above.
Interest expense decreased from $4.9 million in the third quarter of fiscal 2002 to $4.0 million in the third quarter of fiscal 2003. This was due to lower average debt levels and lower interest rates on our variable rate debt.
The effective tax rate is 33.5% in fiscal 2003 and fiscal 2002.
Nine months ended May 31, 2003
Net sales for the nine months ended May 31, 2003 were $403.9 million compared with $394.2 million for the same period of the prior year.
The Pharmaceutical segment had sales of $243.3 million for the nine month period ended May 31, 2003 compared with $235.9 million for the same period of fiscal 2002. The change in exchange rates increased the year to date fiscal 2003 sales by $28.9 million compared with the year to date sales of fiscal 2002. Excluding the impact of exchange rates, sales for the first nine months of fiscal 2003 declined by $21.5 million, or 9.1%, compared with the first nine months of fiscal 2002. This decline in sales follows the low order intake in fiscal 2002 due to the weak specialty chemical market and slow industrial economy in the U.S., the overall slowing of the European economies and price pressures in Europe for glass-lined vessel business. Year to date orders for this segment increased from $233.2 million in fiscal 2002 to $255.5 million in fiscal 2003. The change in exchange rates increased orders for the nine months ended May 31, 2003 by $43.1 million. Excluding the impact of exchange rates, the orders for the nine months ended May 31, 2003 decreased by $20.8 million, or 8.9%.
The Industrial segment had sales of $91.7 million for the nine month period ended May 31, 2003 compared with $90.0 million in the same period of fiscal 2002. The increased year to date sales can be attributed to some small improvement in the U.S. economy. Year to date incoming orders in this segment were $94.9 compared with year to date orders of $82.4 million in fiscal 2002. The 15.2% improvement in orders is a result of the Tarby acquisition and increased order activity in the U.S. and Asia.
The Energy segment had sales of $68.8 million in the nine month period ended May 31, 2003 compared with $68.4 million in the same period of fiscal 2002, an increase of $0.4 million or 0.6%. Crude oil and natural gas exploration and production activities have begun to increase over the past few months. Incoming orders in this segment increased slightly to $68.7 million in the first nine months of fiscal 2003 compared with $65.4 million in first nine months of fiscal 2002.
12
EBIT for the nine months ended May 31, 2003 was $27.3 million compared with $33.2 million in the nine months ended May 31, 2002.
The Pharmaceutical segment had EBIT of $14.3 million in the first nine months of fiscal 2003 compared with $22.7 million in the first nine months of fiscal 2002. The decline in EBIT is due to the aforementioned $21.5 million decline in year to date sales after considering the impact of exchange rates, and lower selling prices in Europe due to intense competition for glass-lined vessel business.
The Industrial segment had EBIT of $7.3 million in the first nine months of fiscal 2003 compared with $4.7 million in the first nine months of fiscal 2002, an increase of $2.6 million while sales increased by $1.7 million. The increase in EBIT is due to cost reduction programs implemented in fiscal 2002 and improved pricing for aftermarket products.
The Energy segment had year to date EBIT of $14.4 million in fiscal 2003 compared with year to date EBIT of $13.6 million in fiscal 2002, an increase of $0.8 million while sales have increased by $0.4 million for the same period. The improvement in EBIT is again attributed to sales volume increase and cost reduction actions implemented in fiscal 2002.
Year to date interest expense decreased from $13.5 million in fiscal 2002 to $11.7 million in fiscal 2003. This was due to lower average debt levels and lower interest rates on our variable rate debt.
The effective tax rate is 33.5% in fiscal 2003 and fiscal 2002.
13
Liquidity and Capital Resources
On February 10, 2003, we exchanged $40.0 million of 8.0% Convertible Subordinated Notes due 2008 for an equal amount of our existing 6.5% Convertible Subordinated Notes due 2003. The 8.0% Convertible Subordinated Notes are convertible into our common shares at $22.50 per share. On April 16, 2003, we redeemed the remaining $19.7 million of 6.5% Convertible Subordinated Notes. The redemption price was 100% of the principal amount and the redemption date was April 16, 2003. We used proceeds from our revolving credit loan to pay for the redemption.
Cash uses in the first nine months of fiscal 2003 were $9.2 million in semi-annual interest payments due on our Senior Notes and Convertible Subordinated Notes, $0.5 million for variable pay plans, $4.4 million for capital expenditures and $12.5 million for the purchase of Tarby. Cash generated from operations funded these cash uses.
Cash uses in the first nine months of fiscal 2002 were $19.8 million in earnout payment and acquisition costs related to the Romaco acquisition, $9.6 million in semi-annual interest payments due on our Senior Notes and Convertible Subordinated Notes, $2.8 million for variable pay plans, $12.6 million for capital expenditures, and $1.9 million for refinancing fees related to our credit agreement. Cash generated from operations and borrowings under our revolving credit facility funded these cash uses. In addition we received $4.9 million when certain equipment was sold under sale-leaseback arrangements.
Following is information regarding our long-term contractual obligations and other commitments outstanding as of May 31, 2003:
Payments Due by Period | ||||||||||||||||||||
Two to | ||||||||||||||||||||
One year | three | Four to | After five | |||||||||||||||||
Long-term contractual obligations | Total | or less | years | five years | years | |||||||||||||||
(In thousands) | ||||||||||||||||||||
Long-term debt |
$ | 200,004 | $ | 7,346 | $ | 52,658 | $ | 100,000 | $ | 40,000 | ||||||||||
Capital lease obligations |
0 | 0 | 0 | 0 | 0 | |||||||||||||||
Operating leases (1) |
11,000 | 2,400 | 3,800 | 3,000 | 1,800 | |||||||||||||||
Unconditional purchase
obligations |
0 | 0 | 0 | 0 | 0 | |||||||||||||||
Total contractual cash
obligations |
$ | 211,004 | $ | 9,746 | $ | 56,458 | $ | 103,000 | $ | 41,800 | ||||||||||
(1) | Operating leases are estimated as of May 31, 2003, and consist primarily of building and equipment leases. |
Amount of Commitment Expiration Per Period | ||||||||||||||||||||
Two to | ||||||||||||||||||||
One year | three | Four to | After five | |||||||||||||||||
Other commercial commitments | Total | or less | years | five years | years | |||||||||||||||
(In thousands) | ||||||||||||||||||||
Lines of credit |
$ | 0 | $ | 0 | $ | 0 | $ | 0 | $ | 0 | ||||||||||
Standby letters of credit |
27,000 | 27,000 | 0 | 0 | 0 | |||||||||||||||
Guarantees |
0 | 0 | 0 | 0 | 0 | |||||||||||||||
Standby repurchase
obligations |
0 | 0 | 0 | 0 | 0 | |||||||||||||||
Other commercial
commitments |
1,660 | 675 | 925 | 60 | 0 | |||||||||||||||
Total commercial
commitments |
$ | 28,660 | $ | 27,675 | $ | 925 | $ | 60 | $ | 0 | ||||||||||
14
We expect operating cash flow to be adequate for the remainder of fiscal year 2003 operating needs and shareholder dividend requirements. The major cash requirement for the remainder of fiscal 2003 is planned capital expenditures of approximately $4.0 million. Capital expenditures are related to additional production capacity, cost reductions and replacement items.
Market Risk
In our normal operations we have market risk exposure to foreign currency exchange rates and interest rates. There has been no significant change in our exposure to these risks, which has been previously disclosed.
Forward-looking Statements
In addition to historical information, this report contains forward-looking statements identified by use of words such as expects, anticipates, estimates, and similar expressions. These statements reflect our expectations at the time this report was issued. Actual events and results may differ materially from those described in the forward-looking statements. Among the factors that could cause material differences are significant declines in capital expenditures in specialty chemical and pharmaceutical industries, a major decline in oil and natural gas prices, foreign exchange rate fluctuations, continued availability of acceptable acquisition candidates, access to capital and financing and general economic conditions that can affect demand in the process industries. We undertake no obligation to update or revise any forward-looking statement.
15
Item 4. Controls and Procedures
(a) | Based on a recent evaluation, which was performed within 90 days of the filing of this Quarterly Report on Form 10-Q, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-14 and 15d-14) are effective in timely alerting them to material information relating to us (including our consolidated subsidiaries) required to be included in periodic reports filed under the Securities Exchange Act. | ||
(b) | There have been no significant changes in our internal controls or in other factors that could significantly affect these controls subsequent to May 31, 2003. |
16
Part IIOther Information
Item 6. Exhibits and Reports on Form 8-K
a) | Exhibits see INDEX TO EXHIBITS | ||
b) | Reports on Form 8-K. During the quarter ended May 31, 2003, we filed a Report on Form 8-K on March 14, 2003 to announce the redemption of our outstanding 6.50% Convertible Subordinated Notes. |
17
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ROBBINS & MYERS, INC. | ||||
DATE: | July 1, 2003 | BY | /s/ Kevin J. Brown Kevin J. Brown Vice President and Chief Financial Officer (Principal Financial Officer) |
|
DATE: | July 1, 2003 | BY | /s/ Thomas J. Schockman Thomas J. Schockman Corporate Controller (Principal Accounting Officer) |
18
CERTIFICATIONS
I, Gerald L. Connelly, certify that:
1. | I have reviewed this quarterly report on Form 10-Q of Robbins & Myers, Inc. (the Registrant). | |
2. | Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstance under such statements were made, not misleading with respect to the period covered by this quarterly report; | |
3. | Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this quarterly report; | |
4. | The Registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Registrant and have: |
a) | designed such disclosure controls and procedures to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; | ||
b) | evaluated the effectiveness of the Registrants disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the Evaluation Date); and | ||
c) | presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date; |
5. | The Registrants other certifying officer and I have disclosed, based on our most recent evaluation, to the Registrants auditors and the audit committee of the Registrants board of directors (or persons performing the equivalent functions): |
a) | all significant deficiencies in the design or operation of internal controls which could adversely affect the Registrants ability to record, process, summarize and report financial data and have identified for the Registrants auditors any material weaknesses in internal controls; and | ||
b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrants internal controls; and |
6. | The Registrants other certifying officer and I have indicated in this quarterly report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses. |
Date: |
July 1, 2003 |
|||
/s/ Gerald L. Connelly Gerald L. Connelly President and Chief Executive Officer |
19
CERTIFICATIONS
I, Kevin J. Brown, certify that:
1. | I have reviewed this quarterly report on Form 10-Q of Robbins & Myers, Inc. (the Registrant). | |
2. | Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstance under such statements were made, not misleading with respect to the period covered by this quarterly report; | |
3. | Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this quarterly report; | |
4. | The Registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Registrant and have: |
a) | designed such disclosure controls and procedures to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; | ||
b) | evaluated the effectiveness of the Registrants disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the Evaluation Date); and | ||
c) | presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date; |
5. | The Registrants other certifying officer and I have disclosed, based on our most recent evaluation, to the Registrants auditors and the audit committee of the Registrants board of directors (or persons performing the equivalent functions): |
d) | all significant deficiencies in the design or operation of internal controls which could adversely affect the Registrants ability to record, process, summarize and report financial data and have identified for the Registrants auditors any material weaknesses in internal controls; and | ||
e) | any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrants internal controls; and |
6. | The Registrants other certifying officer and I have indicated in this quarterly report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses. |
Date: |
July 1, 2003 |
|||
/s/ Kevin J. Brown Kevin J. Brown Vice President and Chief Financial Officer |
20
INDEX TO EXHIBITS
(99) OTHER EXHIBITS
99.1 |
Certification of Chief Executive Officer of Robbins & Myers, Inc. in accordance with Section 906 of the Sarbanes-Oxley Act of 2002 |
|
99.2 |
Certification of Chief Financial Officer of Robbins & Myers, Inc. in accordance with Section 906 of the Sarbanes-Oxley Act of 2002 |
21